New Partnership Aims to Make Advanced Pet Healing Mainstream

By Cynthia Ward

DUBLIN, OH – June 01, 2026 – A new strategic alliance is poised to significantly broaden access to advanced regenerative medicine for pets and horses across the United States. epiq Animal Health, a solutions-focused distributor, has entered into an exclusive U.S. distribution agreement with Vetirus Animal Health, a biopharmaceutical firm specializing in regenerative therapies. The deal centers on Vetirus’s flagship product, Rebound™ High Performance PRP, a therapy designed to accelerate healing in animals with orthopedic conditions.

This partnership signals a potentially pivotal moment for veterinary medicine, aiming to move powerful regenerative treatments from niche specialty clinics into the mainstream of everyday practice. By combining Vetirus’s innovative, FDA-registered product with epiq’s extensive distribution network, the collaboration seeks to solve key logistical and educational hurdles that have historically limited the adoption of such therapies.

Democratizing Advanced Healing

At the heart of the agreement is Rebound™ High Performance PRP (Platelet-Rich Plasma). The therapy involves concentrating a patient's own platelets from a blood sample and reinjecting them into an injured area. These platelets release a cocktail of natural growth factors that can accelerate healing, reduce inflammation, and support tissue regeneration. It’s a technique widely used for common and often debilitating conditions like osteoarthritis, partial cruciate ligament tears, and tendon damage.

What sets Rebound™ PRP apart, and what makes this partnership so significant, is its focus on accessibility. Vetirus has engineered the system to be fast, with a processing time of about 20 minutes from blood draw to injection, and easy to use. Crucially, it requires no dedicated, expensive capital equipment, as it is compatible with standard centrifuges found in most veterinary clinics. This removes a major financial barrier for veterinarians who wish to offer advanced treatments but are hesitant to invest in costly, single-use machinery.

“We are thrilled to partner with epiq Animal Health as our exclusive U.S. distributor,” Robert N. Jordan, Chief Executive Officer of Vetirus, stated in the announcement. “epiq’s unmatched reach, technical expertise, and commitment to advancing veterinary medicine make them the ideal partner to scale Rebound PRP.”

The product's market position as a cost-effective option further fuels its potential for widespread adoption. While regenerative treatments like stem cell therapy can cost thousands of dollars, PRP is generally a more affordable alternative. By positioning Rebound™ PRP as a highly accessible and economically viable option, the companies are directly addressing the needs of veterinarians and pet owners seeking effective, non-pharmaceutical solutions for chronic pain and injury.

A Strategic Alliance to Reshape the Market

The partnership is a textbook example of strategic synergy. Vetirus brings to the table a clinically validated, innovative product in a high-growth sector. The animal regenerative medicine market is expanding, driven by an aging pet population and a growing willingness among owners to invest in their animals' quality of life. However, having a great product is only half the battle; getting it into the hands of professionals is the other.

This is where epiq Animal Health’s role becomes critical. As a “value-added distributor,” epiq provides more than just logistics. Its model focuses on creating supply chain efficiencies and executing go-to-market strategies for innovative products. Jordan’s praise of epiq’s “unmatched reach” underscores the importance of a robust, established network to achieve rapid and widespread market penetration. For Vetirus, this means its novel therapy won't languish on the sidelines but will be actively introduced and supported across a vast network of specialty and equine veterinary practices.

For epiq, the deal enriches its portfolio with a cutting-edge product that aligns perfectly with its mission to connect veterinarians with science-backed innovations. By championing a product that solves real-world clinical problems in an accessible way, epiq reinforces its reputation as a key partner for manufacturers and a vital resource for veterinary professionals.

Overcoming Hurdles with Education and Support

Historically, the adoption of new medical technologies in any field faces challenges, and veterinary medicine is no exception. Veterinarians are rightly cautious, demanding strong clinical evidence, clear protocols, and reliable support before integrating a new treatment into their practice. The variability in efficacy of some earlier PRP systems and a lack of standardized protocols have been points of concern in the field.

The epiq-Vetirus partnership explicitly acknowledges these hurdles. The companies have committed to working together to provide the “clinical proof, education, and supply certainty that veterinarians need to confidently integrate regenerative therapies into everyday practice.” This commitment goes beyond simple sales and marketing. It implies a plan to offer training, share clinical data from university validations, and ensure a reliable supply chain so that clinics can depend on the product's availability.

By proactively addressing the need for education, the alliance aims to build trust and lower the barrier to entry for general practitioners who may have previously viewed regenerative medicine as too complex or specialized for their clinics. This educational push is essential for transforming Rebound™ PRP from a niche product into a standard tool for managing orthopedic health in animals.

The collaboration promises a new chapter for animal care, where advanced, minimally invasive therapies become a routine option for treating injuries and managing chronic pain. As Rebound™ PRP becomes more readily available through epiq’s distribution channels, countless dogs, horses, and other companion animals suffering from orthopedic ailments may soon have a better, more accessible path to recovery.